Tempus AI, Inc. Class A stock analysis
Want to see TEM full AI Analyst Report?
Tempus AI, Inc. Class A (TEM) Stock Price & Analysis
TEM Stock Chart & Stats
- Day’s Range
- $68.48 - $75.83
- 52-Week Range
- $40.77 - $89.09
- Previous Close
- $75.89
- Volume
- N/A
- Average Volume (3M)
- 6.71M
- Market Cap
- $13.84B
- Enterprise Value
- $15.64B
- Total Cash (Recent Filing)
- $637.35M
- Total Debt (Recent Filing)
- $1.43B
- Price to Earnings (P/E)
- ―
- Beta
- 2.30
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- 0.03
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Broad Revenue Growth
Broad-based growth across diagnostics and data applications indicates that Tempus is scaling more than one revenue stream. Continued adoption of testing and analytics can expand the platform’s commercial reach and support durable growth over the next several quarters.
Multi-Year Data Partnerships
Long-term collaborations provide greater revenue visibility than episodic data purchases and deepen Tempus’s relationships with major life sciences customers. These agreements can support recurring data revenue while increasing the strategic value of its healthcare information platform.
Large Multimodal Data Platform
The scale and breadth of Tempus’s multimodal dataset can strengthen its usefulness for clinical decisions, biomarker work, and drug development. A larger data network may improve analytical capabilities and reinforce the platform’s differentiation as usage expands.
Bears Say
Persistent Unprofitability
Tempus continues to generate operating and net losses, so revenue growth has not yet translated into durable profitability. Until cost discipline and gross profit growth consistently cover investments, earnings remain sensitive to execution and the pace of business maturation.
Negative Cash Generation
Ongoing cash consumption reduces the company’s ability to fund expansion entirely from operations and increases reliance on liquidity or financing capacity. Persistent negative free cash flow could constrain strategic flexibility if investments remain elevated or losses take longer to reverse.
Leverage And Reimbursement Exposure
High leverage limits financial flexibility while reimbursement dependence can delay broader adoption of new diagnostic offerings. The combination raises execution risk because Tempus must improve test economics and grow into its obligations while continuing to invest.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
What is Tempus AI, Inc. Class A’s market cap?
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
How were Tempus AI, Inc. Class A’s earnings last quarter?
Is Tempus AI, Inc. Class A overvalued?
Does Tempus AI, Inc. Class A pay dividends?
What is Tempus AI, Inc. Class A’s EPS estimate?
How many shares outstanding does Tempus AI, Inc. Class A have?
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
What is the TipRanks Smart Score and how is it calculated?
Tempus AI, Inc. Class A Stock Smart Score
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky
- Employees
- 3,800
- Website
- www.tempus.com
- Address
- 600 West Chicago Avenue, Chicago, IL, 60654, US
Tempus AI, Inc. Class A (TEM) Earnings & Revenues
TEM Company Deck
TEM Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, led by 23% total revenue growth, 33% data and applications growth, 32% oncology volume growth, major multiyear collaborations, positive adjusted EBITDA, raised revenue guidance, and expanding data-platform scale. The principal challenges were the hereditary business lapping unusually high prior growth, reimbursement dependence, Personalis' current losses and delayed MRD sales-force expansion, and the limited scale expected from the clinical trial matching and CRO businesses. Highlights significantly outweighed the lowlights.
View all TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 5 | 8 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 5 | 0 | 7 |














